Tamoxifen for Sleep
Tamoxifen (Nolvadex) is a nonsteroidal SERM and the primary approved endocrine therapy for hormone receptor-positive breast cancer. Its use in males during or after testosterone therapy to manage gynecomastia or restore the hypothalamic-pituitary axis is off-label.
Why Tamoxifen for sleep?
Tamoxifen (Nolvadex) is a nonsteroidal SERM and the primary approved endocrine therapy for hormone receptor-positive breast cancer. Its use in males during or after testosterone therapy to manage gynecomastia or restore the hypothalamic-pituitary axis is off-label.
Sleep context: Modulating sleep architecture, slow-wave sleep depth, and circadian regulation. Tamoxifen fits this goal because its category (TRT) and benefit profile align with the underlying mechanism.
Benefits relevant to sleep
- Studied off-label in males for management of gynecomastia and post-cycle restoration of gonadotropin axis (prescriber-directed)
Reference dosing by bodyweight
Anchored to the most-cited research dose (250 mcg @ 75 kg). Reference only.
| Bodyweight band | Reference dose range |
|---|---|
| <60 kg / <132 lb | 156–211 mcg |
| 60–75 kg / 132–165 lb | 191–259 mcg |
| 75–90 kg / 165–198 lb | 234–316 mcg |
| 90–105 kg / 198–231 lb | 276–374 mcg |
| >105 kg / >231 lb | 319–431 mcg |
Side effects to weigh against sleep benefit
- Hot flashes and vasomotor symptoms
- Venous thromboembolic events (VTE), including deep vein thrombosis and pulmonary embolism
- Endometrial cancer and uterine sarcoma risk (increased in women on long-term therapy)
- Cataracts and other ocular effects
- Mood changes
- Nausea
Educational use only
This calculator is provided for research and educational purposes. Outputs are derived from the values you enter. Always verify your math and consult a licensed physician before acting on any result.